Daniel P Ashley MPA, BSc, Theodor Borgovan MD, Hyung Sun Yoo MBA, Xin Zhang MD, PhD, Samantha Ahrens, Qingyang Luo, Li Huan MD, John Cole MD, Li Li MD, PhD
{"title":"Identification of Follicular Lymphoma Stem Cell Biomarkers","authors":"Daniel P Ashley MPA, BSc, Theodor Borgovan MD, Hyung Sun Yoo MBA, Xin Zhang MD, PhD, Samantha Ahrens, Qingyang Luo, Li Huan MD, John Cole MD, Li Li MD, PhD","doi":"10.1016/j.jnma.2024.07.051","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>Despite recent advances in identifying clinical risk factors for follicular lymphoma (FL), there remains a need for prognostic and predictive biomarkers. In this study, our objective was to identify biomarkers that are reliable indicators of FL relapse and overall survival via high-throughput screening using tissue microarray (TMA).</p></div><div><h3>Methods</h3><p>Records of patients diagnosed with FL between 1982 and 2009 were examined, with results sorted based on survival post-diagnosis. Corresponding patient biopsies were collected to create TMAs for high-throughput immunohistochemistry (IHC) screening of putative FL cancer stem cell (F-SC) markers (ABCG2, Ki67, OCT3/4) and CD20. Positivity was analyzed via digital batch processing method using Image-Pro software and microscopy.</p></div><div><h3>Results</h3><p>Fifty-nine patients were partitioned into short -(<5 years, n=26) and long- (>15 years, n=33) survival groups. IHC results showed there was no statistically significant difference in CD20 expression (p=0.6378). The results showed an increased expression pattern with significance for all 3 FL-SC markers. Compared with the long-survival group, the short-survival group had significantly higher expression levels of Ki67 (p=0.0275), ABCG2 (p=0.0251) and OCT3/4 (p=0.0226), as well as the combination of all three biomarkers (p=0.0229).</p></div><div><h3>Conclusion</h3><p>The prognostic biomarkers for FL identified may be used to distinguish those patients who are at greatest risk of relapse and in need of the most aggressive and novel therapies. Qualified prognostic markers for FL may direct clinical decision paradigms on which patients are favorable candidates for early therapy, and will obtain additional insight in the development of targeted regiments and treatment protocols to ameliorate outcomes.</p></div>","PeriodicalId":17369,"journal":{"name":"Journal of the National Medical Association","volume":"116 4","pages":"Page 433"},"PeriodicalIF":2.5000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the National Medical Association","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0027968424001329","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction
Despite recent advances in identifying clinical risk factors for follicular lymphoma (FL), there remains a need for prognostic and predictive biomarkers. In this study, our objective was to identify biomarkers that are reliable indicators of FL relapse and overall survival via high-throughput screening using tissue microarray (TMA).
Methods
Records of patients diagnosed with FL between 1982 and 2009 were examined, with results sorted based on survival post-diagnosis. Corresponding patient biopsies were collected to create TMAs for high-throughput immunohistochemistry (IHC) screening of putative FL cancer stem cell (F-SC) markers (ABCG2, Ki67, OCT3/4) and CD20. Positivity was analyzed via digital batch processing method using Image-Pro software and microscopy.
Results
Fifty-nine patients were partitioned into short -(<5 years, n=26) and long- (>15 years, n=33) survival groups. IHC results showed there was no statistically significant difference in CD20 expression (p=0.6378). The results showed an increased expression pattern with significance for all 3 FL-SC markers. Compared with the long-survival group, the short-survival group had significantly higher expression levels of Ki67 (p=0.0275), ABCG2 (p=0.0251) and OCT3/4 (p=0.0226), as well as the combination of all three biomarkers (p=0.0229).
Conclusion
The prognostic biomarkers for FL identified may be used to distinguish those patients who are at greatest risk of relapse and in need of the most aggressive and novel therapies. Qualified prognostic markers for FL may direct clinical decision paradigms on which patients are favorable candidates for early therapy, and will obtain additional insight in the development of targeted regiments and treatment protocols to ameliorate outcomes.
期刊介绍：
Journal of the National Medical Association, the official journal of the National Medical Association, is a peer-reviewed publication whose purpose is to address medical care disparities of persons of African descent.
The Journal of the National Medical Association is focused on specialized clinical research activities related to the health problems of African Americans and other minority groups. Special emphasis is placed on the application of medical science to improve the healthcare of underserved populations both in the United States and abroad. The Journal has the following objectives: (1) to expand the base of original peer-reviewed literature and the quality of that research on the topic of minority health; (2) to provide greater dissemination of this research; (3) to offer appropriate and timely recognition of the significant contributions of physicians who serve these populations; and (4) to promote engagement by member and non-member physicians in the overall goals and objectives of the National Medical Association.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
